Display options
Cite
Massanella M, Ignacio RAB, Lama JR, et al. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe. 2021;2(5):e198-e209doi: 10.1016/s2666-5247(21)00010-0.
Massanella, M., Ignacio, R. A. B., Lama, J. R., Pagliuzza, A., Dasgupta, S., Alfaro, R., Rios, J., Ganoza, C., Pinto-Santini, D., Gilada, T., Duerr, A., & Chomont, N. (2021). Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. The Lancet. Microbe, 2(5), e198-e209. https://doi.org/10.1016/s2666-5247(21)00010-0
Massanella, Marta, et al. "Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study." The Lancet. Microbe vol. 2,5 (2021): e198-e209. doi: https://doi.org/10.1016/s2666-5247(21)00010-0
Massanella M, Ignacio RAB, Lama JR, Pagliuzza A, Dasgupta S, Alfaro R, Rios J, Ganoza C, Pinto-Santini D, Gilada T, Duerr A, Chomont N. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe. 2021 May;2(5):e198-e209. doi: 10.1016/s2666-5247(21)00010-0. Epub 2021 Mar 23. PMID: 34841369; PMCID: PMC8622834.
Copy Download .nbib Format: NLM
Share it on

Lancet Microbe. 2021 May;2(5):e198-e209. doi: 10.1016/s2666-5247(21)00010-0. Epub 2021 Mar 23.

Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study.

The Lancet. Microbe

Marta Massanella, Rachel A Bender Ignacio, Javier R Lama, Amélie Pagliuzza, Sayan Dasgupta, Ricardo Alfaro, Jessica Rios, Carmela Ganoza, Delia Pinto-Santini, Trupti Gilada, Ann Duerr, Nicolas Chomont

Affiliations

  1. (M Massanella PhD, N Chomont PhD); (M Massanella, A Pagliuzza MSc, N Chomont); (R A Bender Ignacio MD, S Dasgupta PhD, D Pinto-Santini PhD, T Gilada MD, Prof A Duerr MD); (R A B Ignacio, Prof A Duerr); (J R Lama MD, R Alfaro MS, J Rios MS, C Ganoza MD).

PMID: 34841369 PMCID: PMC8622834 DOI: 10.1016/s2666-5247(21)00010-0

Abstract

BACKGROUND: Early antiretroviral therapy (ART) initiation (ie, within 3 months of infection) limits establishment of the HIV reservoir. However, the effect of early ART initiation on the long-term dynamics of the pool of infected cells remains unclear.

METHODS: In this longitudinal analysis, we included cisgender men who have sex with men (MSM) and transgender women (aged 18-54 years) at high risk for HIV infection, enrolled in the ongoing longitudinal MERLIN study in Peru between Oct 28, 2014, and Nov 8, 2018. Participants were eligible if they had been infected with HIV less than 90 days before enrolment, and if they had cryopreserved peripheral blood mononuclear cell (PBMC) samples. Participants were stratified into three groups on the basis of whether they initiated ART at 30 days or less (acute group), at 31-90 days (early group), or more than 24 weeks (deferred group) after the estimated date of detectable infection. PBMC samples were collected before ART initiation and longitudinally for up to 4 years on ART. The main outcomes were to establish the size of the HIV reservoir before ART initiation and to assess the effect of the timing of ART initiation on the decay of the HIV reservoir over 4 years follow-up. We quantified viral load, and isolated CD4 cells to quantify total HIV DNA, integrated HIV DNA and 2-long terminal repeat circles. Longitudinal analysis of active and inducible HIV reservoirs were measured by quantifying the frequency of CD4 cells producing multiply-spliced HIV RNA ex vivo and after in-vitro stimulation with a tat/rev induced limiting dilution assay (TILDA). A mixed-effects model from the time of ART initiation was used to measure longitudinal decays in viral loads and each HIV reservoir measure in each of the three groups.

FINDINGS: We included 56 participants in this analysis, all of whom were MSM: 15 were in the acute group, 19 were in the early group, and 22 were in the deferred group. Participants in all three groups had similar levels of all HIV reservoir markers before ART initiation. All participants, including those in the acute group, had a pool of transcriptionally silent HIV-infected cells before ART initiation, as indicated by a substantial increase in TILDA measures upon stimulation. Longitudinal analysis over 4 years of ART revealed a biphasic decay of all HIV persistence markers, with a rapid initial decline followed by a slower decay in all participants. During the first-phase decay, the half-lives of both total and integrated HIV DNA and TILDA measures were significantly shorter in the acute group than in the early and deferred groups. During the second-phase decay, HIV reservoir markers continued to decline only in participants in the acute group.

INTERPRETATION: Participants who initiated ART within 30 days or less of HIV infection showed a steeper and more sustained decay in HIV reservoir measures, suggesting long-term benefit of acute ART initiation on reservoir clearance.

FUNDING: The US National Institutes of Health and the Canadian Institutes for Health Research.

Conflict of interest statement

Declaration of interests We declare no competing interests.

References

  1. Science. 1997 Nov 14;278(5341):1291-5 - PubMed
  2. N Engl J Med. 2016 Jun 2;374(22):2120-30 - PubMed
  3. AIDS. 2014 Jan 28;28(3):325-34 - PubMed
  4. J Antimicrob Chemother. 2020 Aug 1;75(8):2258-2263 - PubMed
  5. AIDS. 2000 Dec 22;14(18):2805-12 - PubMed
  6. Nat Commun. 2019 Jun 21;10(1):2737 - PubMed
  7. J Infect Dis. 2019 Mar 15;219(7):1084-1094 - PubMed
  8. J Immunol Methods. 2002 Dec 1;270(1):109-18 - PubMed
  9. Science. 1997 Nov 14;278(5341):1295-300 - PubMed
  10. EBioMedicine. 2015 Jun 27;2(8):874-83 - PubMed
  11. AIDS. 2015 May 15;29(8):911-9 - PubMed
  12. Lancet Infect Dis. 2015 Apr;15(4):387-96 - PubMed
  13. J Antimicrob Chemother. 2013 May;68(5):1169-78 - PubMed
  14. Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8869-73 - PubMed
  15. Nat Commun. 2020 Aug 14;11(1):4089 - PubMed
  16. J Infect Dis. 2000 Dec;182(6):1636-42 - PubMed
  17. Proc Natl Acad Sci U S A. 2003 Apr 15;100(8):4819-24 - PubMed
  18. Clin Infect Dis. 2021 Mar 15;72(6):1042-1050 - PubMed
  19. Elife. 2020 Oct 06;9: - PubMed
  20. AIDS. 2016 Jul 31;30(12):1943-50 - PubMed
  21. PLoS One. 2012;7(3):e33948 - PubMed
  22. Clin Infect Dis. 2015 Jun 1;60(11):1715-21 - PubMed
  23. Sci Transl Med. 2020 Mar 4;12(533): - PubMed
  24. Antivir Ther. 2011;16(4):535-45 - PubMed
  25. AIDS. 2003 Sep 5;17(13):1871-9 - PubMed
  26. J Virol. 2014 Sep 1;88(17):10056-65 - PubMed
  27. Nature. 2014 Aug 7;512(7512):74-7 - PubMed
  28. PLoS Pathog. 2016 Apr 15;12(4):e1005545 - PubMed
  29. Nat Med. 2003 Jun;9(6):727-8 - PubMed
  30. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):303-13 - PubMed
  31. JCI Insight. 2020 Feb 27;5(4): - PubMed
  32. Nat Med. 2018 Sep;24(9):1430-1440 - PubMed
  33. J Infect Dis. 2005 May 1;191(9):1410-8 - PubMed
  34. Sci Transl Med. 2017 Feb 15;9(377): - PubMed
  35. J Exp Med. 1999 Sep 20;190(6):841-50 - PubMed
  36. AIDS. 2001 Nov 23;15(17):2245-50 - PubMed
  37. EBioMedicine. 2016 Sep;11:68-72 - PubMed
  38. Am J Epidemiol. 2018 Aug 1;187(8):1577-1585 - PubMed
  39. Nature. 2015 Jan 15;517(7534):381-5 - PubMed
  40. J Exp Med. 2020 Jul 6;217(7): - PubMed
  41. PLoS Med. 2017 Nov 7;14(11):e1002417 - PubMed
  42. AIDS. 2011 Nov 13;25(17):2069-78 - PubMed
  43. Nat Med. 1999 May;5(5):512-7 - PubMed
  44. BMC Infect Dis. 2019 Oct 26;19(1):894 - PubMed
  45. Cell Metab. 2019 Mar 5;29(3):611-626.e5 - PubMed
  46. Nat Med. 2018 Jul;24(7):923-926 - PubMed
  47. J Virol. 2005 Feb;79(4):2199-210 - PubMed
  48. Proc Natl Acad Sci U S A. 2012 Jun 12;109(24):9523-8 - PubMed
  49. J Virol. 2014 Nov;88(21):12385-96 - PubMed

Publication Types

Grant support